-Updated sponsor information and added EUDRA No. -The randomized portion of the trial was stopped and all subjects had to receive GW786034. The objectives and data analysis were clarified to define the response rate calculation -Updated new treatment approvals -Included birth control requirements for males in inclusion/exclusion criteria -Clarified upper limit of allowed warfarin dosing -Urine serum pregnancy testing was allowed on Day 1. Added assessments for albumin, inorganic phosphate and magnesium. Subjects had free T3 and T4 assessment if TSH was abnormal. Clarified timing of visit windows, screening period events and the continuation visit phase events -Bone scan was planned to be obtained for all subjects at baseline. If the baseline scan was positive, a repeat scan had to be obtained at the time of the confirmation of a CR or PR. If the scan was negative, a repeat scan was not required. The scans at week 12 and 24 were removed. The scans were allowed at any time if clinically indicated -The first disease assessment in the Treatment Phase was planned to be done at week 8 and per time and event schedule. A confirmation of a CR or PR was planned to be conducted at a minimum interval of 4 weeks from the scan that initially revealed the CR or PR. The “clock” was reset for subsequent scans which were obtained approximately 8 weeks after the confirmation scan. Disease assessment of brain, thorax, abdomen and pelvis using imaging studies were planned to be obtained at screening and two-part disease assessment of thorax, abdomen and pelvis were planned to be obtained during the treatment periods unless clinically indicated. -Clarified sections 8.1-8.2 regarding concomitant medications for verapamil, pimozide, propafenone and diltiazem. Prohibited erectile dysfunction medications -Clarified disease related outcomes or events reporting -The study included IDMC -Study assessments aligned with the time event schedule -End of randomization clarified in schema

Change 1 – Sponsor information: Updated with new medical monitoring information Change 2 – Visit assessment schedule: Allow subject visits from every 4 weeks to visit every 12 weeks after week 148. Change 3 – Time and events table for visit after week 148: insert new table to address details of the visits after week 148. Change 4 – Investigational Product: Allow subject in the future to transition from 100mg and 500mg tablets to 200mg and/or 400mg tablets.

Change 1 – Remove old information: This amendment permits continued access to clinical trial material for subjects ongoing at the time of implementation of this amendment with adjustment to the frequency of clinical visits, scans and labs. Patient treatment and disease management will be at the discretion of the treating physician and as indicated by local standard of medical care of local standard of medical care and local approved labeling (or the DCSI). Change 2 – Data Collection: Investigators will only be required to collect and report to the Sponsor SAEs, pregnancies and non-serious AEs leading to IP discontinuation, other reasons leading to IP withdrawal and any non-serious AEs the investigator deems important to report using the forms provided. Collection of additional safety information will no longer be required by the Sponsor but will be at the discretion and judgment of the investigator. Change 3 – Sponsor information: Updated with new medical monitor information.

This amendment changes the description of the investigational product GW786034 to: pazopanib monohydrochloride salt is supplied as aqueous film-coated tablets containing either 200mg or 400mg of the free base. Both the 200mg and the 400mg tablets are oval shaped and white in color. Refer to the pazopanib IB for information regarding the physical and chemical properties of pazopanib and a list of excipients.